Efficacy and Safety of Subcutaneous Administration of Fremanezumab for Migraine

Study Title
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Teva Identifier
TV48125-CNS-30051 | 2015-004550-18
ClinicalTrials.gov Identifier
NCT02638103
Study Status
Completed
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 70 Years
Trial Duration
February 26, 2016 - December 8, 2018
Phase
Phase 3

Study Type

Interventional